Medication information for patients








Development and Distribution of Patient Medication Information for

9/20/2014
03:14 | Author: Allison King

Medication information for patients
Development and Distribution of Patient Medication Information for

FDA has determined that the current system is not adequate to ensure that patients receive the essential medication information that is needed to use the drug.

Part 15 Public Hearing: Patient Labeling / Consumer Medication Information (Day 2): https://collaboration. /p /.

Under the current system, patients may receive several different types of information, developed by different sources that may be duplicative, incomplete, or difficult to read and understand. The purpose of this hearing is to solicit public input on processes and procedures for standardizing PMI using a quality system approach for monitoring development and distribution of PMI.

Comments (1)Read more



Postmarket Drug Safety Information for Patients and Providers

7/19/2014
01:12 | Author: Jeremy Rodriguez

Medication information for patients
Postmarket Drug Safety Information for Patients and Providers

Postmarket Drug Safety Information for Patients and Providers. In accordance with Section 915 of the Food and Drug Administration Amendments Act of 2007.

In accordance with Section 915 of the Food and Drug Administration Amendments Act of 2007 (FDAAA), this website contains links to postmarket drug safety information to improve transparency and communication to patients and healthcare providers.

Page Last Updated: 09/08/2014 Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.

Protecting and Promoting Your Health.

Comments (0)

Drug Information for Patients - Cancer Care Ontario

5/18/2014
01:18 | Author: Chloe Allen

Medication information for patients
Drug Information for Patients - Cancer Care Ontario

CCO provides Drug Information Sheets, Symptom Management only – in development) information for patients, their families and caregivers.

For a more comprehensive document search, see Drug Formulary.

French drug information for patients.

They do not replace the advice of your healthcare professional. The information on these pages is maintained by the CCO Drug Formulary Team. The documents provide general information about your treatment. Always discuss your treatment with your health care team. Any use of the information provided herein is subject, at all times, to CCO’s Terms and Conditions.

Read the Frequently Asked Questions.

You should always discuss your care first with your physician. These information sheets are intended as supplemental material, and are not to be used in place of advice from your physician and other healthcare providers. Some of the information in these documents may not apply to all patients or may be relevant only under certain circumstances, since cancer treatments are often very individualized.

Would you like to participate?. Please help improve the quality of our website by answering 10 brief questions in our online survey.

For descriptions of the information sheets, go to About our Documents.

CCO provides Drug Information Sheets, Symptom Management Information Sheets as well as Chemotherapy Regimen (selected breast and lung only – in development) information for patients, their families and caregivers, to help them become informed and active participants in their own care.

The search results display limited information. Please refer to the actual document for detailed information related to your search.

Comments (0)

Consumer Medicine Information - National Council on Patient

3/17/2014
03:04 | Author: Chloe Allen

Medication information for patients
Consumer Medicine Information - National Council on Patient

Patient Medication Information (2008 – 2011). European Medicines Agency Improves Package Leaflets (July 2011) - The European Medicines Agency has.

Click here to read the 4-page notice, which incorporates detailed chronology of CMI activities since the 1970s. is available here. FDA Public CMI Meeting, July 2003 In June 2003, the FDA issued a Federal Register notice announcing that a public meeting on the current status of useful written medicine information for consumers now referred to as consumer medicine information (CMI) would be held in Washington, DC on July 31.

Comments (4)Read more

Labels, patient information leaflets and packaging for medicines

1/16/2014
05:30 | Author: Jeremy Rodriguez

Medication information for patients
Labels, patient information leaflets and packaging for medicines

The Patient Information Quality Unit is part of the Vigilance and Risk Management of Medicines (VRMM) Division. The Unit is responsible for.

Updated labelling may be submitted to MHRA via a notification procedure.

The Patient Information Quality Unit is part of the Vigilance and Risk Management of Medicines (VRMM) Division. The Unit is responsible for policy and regulation of all types of product information.

This page provides an overview of information related to labels, patient information leaflets and packaging for medicines.

Marketing authorisation holders for medicines listed in Schedules 2 and 3, including lisdexamphetamine and tramadol containing medicines should update their packaging as soon as possible, so that packs produced after 10 June 2014 include this symbol.

Control of lisdexamfetamine, tramadol, zaleplon, zopiclone and reclassification of ketamine.

For controlled drugs, outer and immediate packaging subject to full labelling requirements, present the following symbol adjacent to the declaration of legal status (POM). This additional symbol is included on a voluntary basis.

Home How we regulate Medicines Labels, patient information leaflets and packaging.

Information to patients or consumers is provided on the label and, more recently, by patient information leaflets (PILs) - unless all the necessary information can be included on the label. All medicines in the UK have labels and/or PILs approved in line with Title V of Council Directive 2001/83/EC. Information on how a medicine should be used is provided to doctors, pharmacists and nurses in the Summary of Product Characteristics (SPC).

In Medicines.

Comments (0)